# What Makes a Telehealth Landing Page Pass Meta and Google Review?

Reviewed November 9, 2026 · By Michael Borgia, MedScale Health

## Short answer

As of November 2026, a telehealth landing page passes Meta and Google review when it reads as a clinic rather than a pharmacy: the program and prescriber first, medication detail second, and no drug-name headlines or per-drug pricing without certification. MedScale Health, a fractional growth team for US telehealth brands and clinics, builds every page to those rules. Each page also needs a prescription-required statement, provider credentials, a results-vary line and a working privacy policy, because both platforms review the page as part of the ad.

## What does a telehealth landing page need to pass ad review?

- Both platforms review the destination as part of the ad. A compliant ad pointing at a non-compliant page is rejected because of the page.
- The page decides the account's category. A medication menu with prices reads as an online pharmacy and restricts conversion events across the account.
- Every page an ad can land on carries a prescription-required statement, provider credentials, a results-vary line and a real privacy policy.
- [Compounded products are described as compounded](https://medscale.health/answers/compounded-glp-1-marketing-agency), not FDA-approved, and never compared to the branded drug.
- Speed and intake length are conversion problems as much as review problems: landing page experience is part of Google's Quality Score, and every field before the calendar loses some of the people who clicked.

MedScale Health, [a fractional growth team for US telehealth brands and clinics](https://medscale.health/services) that runs paid ads, landing pages, [funnel optimization](https://medscale.health/answers/telehealth-funnel-optimization-agency) and SEO and AEO, [builds and rebuilds telehealth landing pages](https://medscale.health/services/websites-and-landing-pages) because most healthcare sites were built by someone who did neither the policy read nor the intake math, and the ad budget pays for it every month. The rules on this page are what every page is read against. This page is marketing guidance for healthcare operators. It is not medical or legal advice, and platform policies change: check the sources listed at the end before acting on any specific rule.

## Do Meta and Google review the landing page as well as the ad?

Google's destination requirements cover what a final URL may and may not be: it has to work, be crawlable by Google's AdsBot, match the domain in the display URL, stay easy to navigate, and not redirect to a different domain. Landing page experience, one of the parts of Quality Score, measures how relevant and useful the page is to people who click the ad, and Quality Score feeds cost. Meta's drugs and pharmaceuticals standard applies to the ad and to where it leads: a page that promotes prescription drugs is prescription-drug advertising whether or not the ad named the drug, and requires LegitScript certification and Meta's authorization.

Separately from the human reviewer, Meta's systems classify the data source by what the site is about and restrict what a health-associated source may send. Meta makes that classification from the pages, which is why a clinic that added a medication menu sees cost per consult climb without a single ad being rejected. MedScale reads the whole site, not only the landing page, before a campaign launches.

## Which pharmacy signals get a telehealth landing page rejected?

- Drug-name headlines and per-drug pricing tables without certification.
- Buy, order and [add-to-cart language for a prescription product](https://medscale.health/answers/meta-catalog-ads-prescription-products).
- "FDA-approved" on a compounded product, or any claim that it is the same as the branded drug. The FDA's 2026 warning letters to telehealth companies cited exactly those claims.
- Statements of inferiority about appearance, pinched-fat close-ups, timed outcome promises without a qualifier, and second-person copy about the visitor's body or condition. Meta has allowed adults-only weight-loss before-and-after since July 22, 2026, and cosmetic before-and-after was already allowed; MedScale leaves before-and-after out of the ads it builds, as a house rule rather than a Meta rule.
- URLs and page paths that name a drug or a condition where a tracking event might carry them.

## What must every telehealth landing page include?

- The program and the prescriber first: what the visit is, who conducts it, what happens after.
- Medication detail second, framed as options a licensed prescriber may consider, with compounded status stated wherever a compounded product is named.
- A prescription-required statement and the candidacy conditions in plain language.
- Provider credentials, licensing, and [the states served](https://medscale.health/answers/where-to-launch-telehealth-ads-by-state).
- A results-vary line and, where a testimonial appears, a statement of what is typical, in line with FTC guidance on health product claims.
- A real privacy policy, contact details and terms. LegitScript's terms require the privacy policy to be clearly displayed, and reviewers look for all three.
- Once certified, the certification seal in the footer of every page an ad can land on.

MedScale checks every page an ad can reach for each of these elements before the campaign goes live. Pages already running get the same read in MedScale's [free Growth Audit](https://medscale.health/audit), which walks the landing page and intake as a patient would and checks them against Meta's and Google's health rules.

## What health claims can a telehealth landing page make under FTC and FDA rules?

The FTC's health products guidance requires that health claims be truthful, not misleading and substantiated by competent and reliable scientific evidence, with testimonials reflecting typical results or accompanied by a clear statement of what is typical. The FDA's February 2026 warning letters to 30 telehealth companies (posted in March) over compounded GLP-1 marketing cited claims implying sameness with FDA-approved products and branding that implied the telehealth company was the compounder. FDA's June 15, 2026 page for telehealth companies sets out the rest: compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing, must not be called generic or equivalent to approved drugs, must not be promised identical results, and must not be described as coming from an "FDA-approved" pharmacy, because FDA does not approve or license pharmacies. A landing page that would draw either agency's attention also fails LegitScript, so the claim discipline is the same discipline that unlocks certification. MedScale writes page claims to that standard, with compounded status stated wherever a compounded product is named.

## How should the intake path on a telehealth landing page work?

The fewest fields sit before the booking and the qualification questions after it, with the calendar embedded rather than linked out wherever the booking tool allows. Where the patient must click out to an intake platform, the ad click travels with them so the booked visit, not the form fill, is what the campaign gets credit for. Consent language for texting sits on the form, because the speed-to-lead sequence that follows depends on it. MedScale integrates the intake and calendar into the pages it builds, so the booked visit is what each campaign is judged on.

## How fast does a telehealth landing page need to load?

Google's Core Web Vitals set the thresholds a page is measured against: Largest Contentful Paint under 2.5 seconds, Interaction to Next Paint under 200 milliseconds, Cumulative Layout Shift under 0.1. A telehealth page loads under two seconds on a phone or it loses the click it paid for, and the hero image is usually the element that decides it. MedScale tests every page it builds against those thresholds on a phone before ads point at it.

## What should a telehealth landing page send to ad platforms?

Server-side events fire on every step with generic names. No form field or URL that contains a condition reaches an ad platform, no third-party pixel touches a health field, and no names, emails, phone numbers, IP addresses or browser IDs go to the ad platforms. Hosting keeps intake data where a business associate agreement covers it. The data path is documented so a compliance officer can review it. MedScale keeps conditions and drug names out of every final URL its ads point at.

## Does each telehealth ad need its own landing page?

A GLP-1 program and a TRT program need separate pages because the policy rules, the candidacy questions and the intake path differ. Two ads for the same program share a page. [A med spa](https://medscale.health/clinics/med-spa-aesthetics) that adds a prescription weight-loss add-on separates it onto its own page so that the cosmetic pages never fall under the prescription-drug rules. MedScale builds one landing page per campaign offer on that rule.

## How do you audit a telehealth landing page before running ads?

Read the page the way a reviewer does, top to bottom on a phone, and ask one question per screen: does this screen describe a clinic and a program, or does it describe a product for sale? A headline that names a molecule, a pricing table with one row per drug, a button that says order, a compounded product described as FDA-approved or as equivalent to a brand, [an image that invites comparison of bodies](https://medscale.health/answers/patient-before-and-after-photo-consent-for-ads), and a second-person sentence about the visitor's condition are each a pharmacy or a personal-attribute signal. Then open the network tab and read what the page sends when the form is submitted: any field, URL or event name that carries a condition or a drug to an ad platform is a tracking finding, and it is the finding that classifies the account. MedScale starts every page engagement with that read and a written list of what would trigger a restriction.

## Can you fix a telehealth landing page without pausing campaigns?

Most pages can be fixed in the CMS they already live in: headlines rewritten around the program, the medication section moved below the prescriber and reframed as options, the required statements added, the images swapped for process imagery, the event names changed. Those changes go live behind the running campaigns and are followed by a policy read of the ads pointing at the page, because a page that now reads as a clinic exposes any ad that still reads as a pharmacy. A rebuild is scoped only when the structure itself is the problem, when the platform cannot host compliant tracking, or when the site is one page for every program and needs to become one page per offer. MedScale scopes a rebuild only in those cases, and says so before any work starts. In either case the client owns the result: the code, the domain and the hosting account sit in the client's name from the first day.

## How does MedScale build telehealth landing pages that pass review?

MedScale Health's websites and landing pages service (medscale.health/services/websites-and-landing-pages) starts with a policy read of the current site and a written list of what would trigger a restriction, then builds one landing page per campaign to the clinic-first structure on this page, integrates intake and calendar, installs and verifies server-side tracking on every step, and tests one variable at a time on the page that gets the traffic, read against booked consults rather than click-through. Where the whole structure reads as a pharmacy or the platform cannot host compliant tracking, it scopes a rebuild and says so first. The client owns the code, domain and hosting from day one.

## Next step

**Check your ad before Meta does.** Paste your ad copy into the free pre-check. It flags the lines a reviewer reads as personal attributes, outcome promises or drug claims.

- [Run the free pre-check](https://medscale.health/pre-check)
- [Already restricted? Start a rescue](https://medscale.health/rescue)
- [Telehealth marketing agency](https://medscale.health/telehealth)
- [Get a free Growth Audit](https://medscale.health/audit): a written read of your ads, pages and eligibility, with a plan

## FAQ

**Why was our Meta ad rejected when the ad itself was compliant?**

Usually because of the landing page: Meta reviews the destination as part of the ad. A page with inferiority statements, pinched-fat imagery, drug-name pricing or claims that present a compounded product as FDA-approved gets a compliant ad rejected, and a page that reads as a pharmacy classifies the whole account under the drugs standard.

**Can we list our medications and prices on the landing page?**

Not without certification, and carefully even with it. A medication menu with prices and order language is what makes a page read as an online pharmacy. Lead with the program and the prescriber, present medications as options the prescriber may consider, and state compounded status plainly.

**Do we need a separate landing page for every campaign?**

One per offer and audience, not one per ad. Programs with different policy rules, candidacy questions and intake paths need separate pages, and two ads for the same program share one.

**Is a fast page really a compliance issue?**

No, speed is not a policy rule, but a slow page costs money. Landing page experience feeds Google's Quality Score, which affects cost, Core Web Vitals set the speed thresholds, and a page over two seconds on mobile loses patients before any rule applies.

**Will the landing page be HIPAA compliant?**

Only the intake path needs to be. The marketing page is not a covered system, but the intake path is. Form and calendar vendors sit under a business associate agreement, tracking sends only neutral events tied to the ad click, with no names, emails, phone numbers, IP addresses or browser IDs, and no condition or medication appears in a URL or an event name. Document the data path so a compliance officer can review it.

## Sources

- [Google Ads policy: Destination requirements](https://support.google.com/adspolicy/answer/6368661?hl=en) (checked October 5, 2026)
- [Google Ads Help: About Quality Score for Search campaigns (landing page experience)](https://support.google.com/google-ads/answer/2404197?hl=en) (checked October 5, 2026)
- [Meta Advertising Standards: Drugs and pharmaceuticals](https://transparency.meta.com/policies/ad-standards/restricted-goods-services/drugs-pharmaceuticals/) (checked October 5, 2026)
- [FDA press announcement: FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s](https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s) (checked October 5, 2026)
- [FDA (Jun 15, 2026): FDA to telehealth companies, what to know when promoting compounded drugs](https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs) (checked October 5, 2026)
- [FTC: Health products compliance guidance](https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance) (checked October 5, 2026)
- [LegitScript: Healthcare Certification terms and conditions](https://www.legitscript.com/certification/healthcare-certification/terms-and-conditions/) (checked October 5, 2026)
- [web.dev: Web Vitals (LCP, INP, CLS thresholds)](https://web.dev/articles/vitals) (checked October 5, 2026)

## Related

- [How Do You Launch a Telehealth Brand? The Compliance Checklist](https://medscale.health/answers/how-to-launch-a-telehealth-brand-checklist)
- [GLP-1 Ad Examples That Pass Meta Review](https://medscale.health/answers/glp-1-ad-creative-that-survives-review)
- [Meta Disabled Our Healthcare Ad Account. How Do We Get It Back?](https://medscale.health/answers/meta-ad-account-disabled-healthcare-recovery)
- [What Are the Rules for Advertising Compounded Semaglutide in 2026?](https://medscale.health/answers/advertising-compounded-semaglutide-after-shortage-delisting)

Canonical page: https://medscale.health/answers/telehealth-landing-page-compliance